Biogen NASDAQ BIIB has gotten off to a great start in 2017 in some respects The biotech launched promising new spinal muscular atrophy drug SMA Spinraza The Committee for Medicinal Products for Human Use CHMP recommended approval for Spinraza in Europe Biogen 160 spun off
May 08, 2017 at 05:49AM
from
No comments:
Post a Comment